New TB vaccine candidate MTBVAC enters Mid-Stage human trial
NCT ID NCT06997367
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a new tuberculosis vaccine called MTBVAC (BBV169) in 164 healthy adolescents and adults. Some participants get the new vaccine, others get the standard BCG vaccine. The study checks how safe the vaccine is and how well it triggers an immune response, aiming to find a better TB vaccine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MTBVAC (BBV169) vaccine
- What this could lead to
- If successful, this could lead to a more effective tuberculosis vaccine than the current BCG, potentially reducing TB cases worldwide.
- What could go wrong
- This is a mid-stage trial with only 164 participants, so results may not apply broadly. The vaccine is still experimental and may not prove safer or more effective than BCG.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS (TB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AIIMS-Delhi
New Delhi, 110029, India
-
Guru Teg Bahadur Hospital
Delhi, 11009, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a shorter TB regimen transform child care?
- Can a smartphone app lift the shame of TB?
- A mobile x-ray van with AI could spot TB before it spreads
- Can exercise and breathing training repair lungs damaged by TB?
- Community-Driven TB screening aims to reach vulnerable immigrants
- Smartphone Check-Ins could boost TB treatment success